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ABSTRACT 
Rottweilers are predisposed to eosinophilic diseases, including hypereosinophilic syndrome. The immunopathogenesis 
of idiopathic eosinophilia is poorly characterised in dogs and man. Studies in people have suggested cytokines, particu-
larly interleukin (IL)-5, play a role in instigating and perpetuating eosinophilia. This study sought to establish whether 
differences in gene expression, and concentration of selected, cytokines and chemokines were associated with eosino-
philia in Rottweilers. Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) assays were 
used to quantify messenger ribonucleic acid  (mRNA) encoding cytokines IL-4, -5, -10, -12p19, -12p35, -12p40, -18, 
interferon gamma (IFN-γ) and chemokines eotaxin-2 and -3 from peripheral blood mononuclear cell (PMBC) samples 
obtained from healthy dogs (breeds other than Rottweiler) with normal eosinophil blood counts (n = 5) and Rottweilers 
with normal (n = 6), mildly increased (n = 7) and high (n = 3) eosinophil blood counts. Quantification of plasma IFN-γ 
and IL-5 was performed using commercially available canine-specific enzyme-linked immunosorbent assays ELISAs. 
Cytokine mRNA was measurable in all samples, although eotaxin-2 and -3 were not detected. No significant differences 
in gene expression of any cytokine were found between groups (based on eosinophil count or breed). No significant 
difference in plasma IL-5 or IFN-γ concentration was present between groups. In conclusion, there were no significant 
differences in cytokine mRNA profiles or plasma IL-5 and IFN-γ levels between Rottweilers with increased eosinophil 
counts and Rottweiler and non-Rottweiler dogs with normal eosinophil counts. 
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1. Introduction 
Eosinophils play an important role in innate immunity, 
inflammation and homeostatic host responses in dogs [1]. 
Eosinophil granules contain highly cationic proteins with 
cytotoxic and pro-thrombotic properties, and these cells 
are known to incite endothelial damage [1]. In particular, 
eosinophils can produce substances such as platelet acti-
vating factor that can alter bronchial and vascular smooth 
muscle tone, modify vascular permeability and stimulate 
chemotaxis of other inflammatory cells [1,2]. Eosino-
phils respond to different stimuli, particularly parasitic 
infection, where their cellular products can be protective 
to the host [3]. However, exuberant release of cellular 
products by eosinophils can contribute to tissue damage, 
particularly in the respiratory and gastrointestinal tracts 
[4,5]. 
Idiopathic eosinophilic diseases (or eosinophilic infil-
tration in the absence of an identifiable parasitic or aller-
gic trigger) have been described in multiple breeds such 
as German shepherd dogs, Cavalier King Charles span-
iels, Siberian Huskies, Alaskan Malamutes and Rott-
weilers [3-11]. In many reports, Rottweilers appear to be 
overrepresented with idiopathic eosinophilic disease [4]. 
It has been postulated that Rottweilers may have an ex-
aggerated response to allergic stimuli or parasite expo-
sure [4,12]. 
Studies in people with eosinophilic disorders have 
highlighted the role of cytokines, particularly interleukin 
(IL)-5, in mediating eosinophil release [13,14]. IL-5 
forms part of the type-2 (Th2) cytokine profile, and is 
essential for eosinophil maturation, differentiation and 
egress from the bone marrow [1,2]. In people with eosi-
nophilic disorders, exaggerated release of IL-5 by reac-
tive eosinophils has been demonstrated in vivo [5]. The 
chemokines eotaxin-2 (CCL24) and eotaxin-3 (CCL26) 
are also able to induce chemotaxis and release of reactive 
oxygen species in eosinophils via interaction with 
chemokine receptor CCR3 [15-18]. It is unknown what 
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cellular signalling drives the production of hypereosino-
philic syndrome (HES) and other eosinophilic disease in 
dogs, or why Rottweilers are predisposed.  
The aim of this study was to establish if there are de-
finable differences in expression of mRNA encoding 
cytokines and eotaxins, or in plasma concentrations of 
IL-5 and IFN-γ in Rottweilers with variable eosinophil 
counts and healthy dogs of other breeds.  
2. Materials and Methods  
2.1. Animals 
The study was conducted with full Murdoch University 
Animal Ethics Committee approval, based on NHMRC 
guidelines, with signed owner consent obtained. Dogs 
were identified upon presentation to Murdoch University 
Veterinary Hospital, as well as from Rottweilers identi-
fied from a haematological survey of breeding kennels 
performed previously (Mansfield, unpublished observa-
tions 2004). Each dog had a full physical examination, 
with particular focus on the detection of ectoparasites 
and evidence of allergic skin disease. Dogs with eosino-
philia were further assessed for common aetiologies via 
faecal floatation, repeat haematology, heartworm antigen 
testing, skin scraping and an anthelminthic trial. Further 
tests, such as radiography, ultrasonography, adrenocorti-
cotrophic (ACTH)-stimulation tests, fine-needle aspira-
tion of affected organs, bone marrow biopsy or endo-
scopy, were performed on an individual basis, deter-
mined by the animals’ degree of eosinophilia, physical 
examination findings and localising clinical signs.  
2.2. Collection and Processing of Material 
Whole blood was obtained via cephalic or jugular veni- 
puncture into a 2.5 mL EDTA container and three 4.5 
mL lithium heparin containers. A complete blood count 
(CBC) was performed using an automated haematology 
analyser (Advia, Siemens, Germany) and confirmed by a 
manual differential. Heparinised blood samples were 
processed by a 1:1 dilution with physiological saline fol-
lowed by density gradient centrifugation (Lymphoprep, 
Axis-Shield, Norway), to isolate peripheral blood mono-
nuclear cells (PBMC). The pelleted PBMC were washed, 
resuspended in freezing medium (foetal calf serum with 
10% dimethyl sulfoxide) and stored in liquid nitrogen 
until shipped on dry ice for RNA isolation.  
2.3. RNA Isolation 
Total RNA was isolated from PBMC using a Ma-
cherey-Nagel NucleoSpin RNA II Isolation Kit (ABgene, 
Epsom, UK). Further deoxyribonuclease (DNase) diges-
tion of the RNA solution was performed using RQ1 Ri-
bonuclease-Free DNase (Promega Corporation, South-
ampton, UK), as per the manufacturer’s instructions. 
Quantity and quality of resulting RNA was assessed by 
automated gel electrophoresis (Experion, Bio-Rad Labo-
ratories, Hemel Hempstead, UK) prior to storage at 
–70˚C. 
2.4. Primer and Hydrolysis Probe Design 
Primers and probes for chemokines and cytokines were 
designed using Primer 3 [19] and MFold, from the canine 
specific GenBank sequences for IL-12p35 (accession 
number: U49085) and IL-12p19 (accession number: 
XM_538231) as described by Peters et al. (2004) (Table 1) 
[19]. IL-4, -5, -10, -12p19, -12p35, -12p40, -18, interferon 
(IFN)-γ, eotaxin-2 and eotaxin-3 specific assays have 
previously been validated in dogs [20-24]. Assays for 
potential housekeeper genes glyceraldehyde-3-phos- 
phate dehydrogenase (G3PDH), hydroxylmethylbilane syn- 
thase (HMBS), hypoxanthine phosphoribosyl-transferase 1 
(HPRT1), ribosomal protein L13a (RPL13A), ribosomal 
protein S18 (RPS18), succinate dehydrogenase complex, 
subunit A (SDHA), TATA box binding protein (TBP), 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein and zeta polypeptide (YWAZ) were 
performed as described by Peters et al. (2007) [24] (Sup-
plementary Table A1). 
2.5. Quantitative RT-PCR  
Synthesis of complimentary DNA (cDNA) was per-
formed using 500ng of random hexamers with the Im-
Prom-II Reverse Transcription System (Promega Corpo-
ration, Madison, WI), according to the manufacturer’s 
instructions. Quantitative RT-PCR was performed using 
HotStarTaq Master Mix (Qiagen Ltd., Crawley, UK), 
with sample incubations performed in an iCycler IQ 
(Bio-Rad Laboratories Ltd., Hercules, CA) during which 
fluorescence data were collected. The absence of ge-
nomic contamination of the RNA samples and nucle-
ase-free water was confirmed prior to the reverse tran-
scriptase reactions and none of the samples showed evi-
dence of amplifiable genomic DNA with the G3PDH 
qPCR assay.  
In order to determine the most appropriate house-
keeper genes for the study, all 8 potential genes were 
quantified in all cDNA samples. A mean cycle threshold 
(Ct) value was calculated for each PBMC sample using 
the two measured Ct values. The mean Ct value was con-
verted to a relative copy number value using the EΔCt 
method (E: reaction efficiency) with ΔCt values calcu-
lated relative to the sample with the largest Ct (fewest 
gene copies). The geNorm VBA applet for Microsoft 
Excel was used to determine the level of stability of the 
test genes [25].  
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Relative expression data for each of the gene cytokine/ 
chemokine targets was calculated using the gBase app- 
let for Microsoft Excel (http://medgen.ugent.be/qbase/), 
normalised against the 3 most stable housekeeper genes. 
The sample with the fewest gene copies (latest Ct value) 
was given a relative copy number of 1 and all other sam-
ples were given values relative to this sample. These 
relative copy number results were used for the statistical 
testing and presentation in graphical form.  
2.6. Quantification of IFN- and IL-5 Using 
ELISA 
IFN- and IL-5 concentrations were measured in hepari-
nised plasma samples with canine-specific ELISA kits 
for IFN- (R&D Systems, Minneapolis, USA) and IL-5 
(USCN Life Science Inc., USA), according to manufac-
turer’s instructions. 
2.7. Statistical Analysis 
Dogs were categorised as clinically healthy Rottweilers 
with normal eosinophil counts (“RottL”; ≤ 1.0 × 109/L); 
clinically healthy adult Rottweilers with mild increase in  
eosinophil counts (“RottM”; 1.0 - 2.0 × 109/L); Rottweil-
ers that had a moderate to severe increase in eosinophil 
counts (≥ 2.0 × 109/L) (“RottH”); and dogs of other 
breeds with normal eosinophil counts (“N”).  
For each cytokine, a Kruskal-Wallis analysis of vari-
ance and Mann Whitney U-test were performed to ex-
amine differences in relative copy numbers obtained in 
the plasma samples between the groups RottH, RottM, 
RottL and N, between RottL and N, and between RottH 
+ RottM + RottL and N, as well as between RottH + 
RottM and Rott L and N. As the results were not nor-
mally distributed (using a Kolmogorov-Smirnov test), 
non-parametric testing was used to examine differences 
between the groups for each cytokine. The results of each 
group for IL-5 and IFN-γ concentrations were compared 
using unpaired t-tests with unequal variances. For all 
analyses, differences were considered significant when P 
< 0.05. 
The correlation coefficient was calculated to investi-
gate the relation between IL-5 concentration and mRNA.  
3. Results 
3.1. Animals 
There were a total of 21 dogs recruited for the study. 
There were 6 clinically healthy Rottweilers with normal 
eosinophil counts (“RottL”), 7 clinically healthy adult 
Rottweilers with increased eosinophil counts (“RottM”), 
3 Rottweilers with hypereosinophilic disease (“RottH”); 
and 5 healthy dogs of other breeds with normal eosino-
phil counts (“N”). The other breeds included 1 English 
springer spaniel, 2 Whippets, 1 Greyhound and a Labra-
dor crossbreed dog. The mean age of Rottweilers in 
groups RottM and RottH was 2.5 years (range 1 to 4 
years), compared to a mean age of 3.27 years (range 1 to 
6 years) of dogs in RottL and N respectively. There were 
four males (three entire) and one female (neutered) in N, 
four females (all entire) and two males (both neutered) in 
RottL, five females (one neutered) and two males (both 
entire) in RottM, and one neutered male and two females 
(one neutered, one entire) in RottH. The majority of 
Rottweilers were breeding animals kept in kennel situa-
tions. 
3.2. Quantitative RT-PCR 
Transcripts of cytokines IL-4, -5, -10, -12p19, -12p35, 
-12p40, -18, and IFN-γ could be quantified in all of the 
samples, but mRNA encoding eotaxins-2 and -3 were not 
detected in any sample. All samples were positive for the 
housekeeper genes tested. RPL13A, SDHA and YWAZ 
were selected as the most stably expressed genes for use 
in normalisation of the expression data (Table 1). 
Plots of relative copy numbers for IL-5 and IFN- are 
shown in Figures 1 and 2, respectively. There were no 
significant differences in mRNA encoding between the 
groups for any cytokine. Despite a tendency for IFN- 
mRNA expression to be lower in RottH/RottM versus 
RottL/N, this did not reach statistical significance (P= 
0.062). 
3.3. Quantification of IFN- by ELISA 
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Figure 1. Plots of the relative copy number from QRT-PCR 
assays for IL-5. The horizontal line corresponds to the me-
dian value of that group. There were no significant differ-
ences in the transcription of mRNA encoding IL-5 between 
the groups. 
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Rottweilers with increased eosinophil count did not cor-
relate with changes in the plasma concentration of IFN-γ. 
The majority of dogs had IFN- concentrations below the 
minimum detectable level of the assay (Figure 3). Only 
3/7 dogs from group RottM had measurable IFN- con-
centrations (16.45, 48.71, and 51.47 pg/mL). There were 
no significant differences between normal and diseased 
animals in the concentration of plasma IFN-γ. 
3.4. Quantification of IL-5 by ELISA 
Plasma IL-5 was detectable in 11 dogs. The median con-
centrations of IL-5 concentrations detected in RottH + 
RottM versus RottL+N were 14.325 pg/mL and 0.0 
pg/mL respectively. The median concentrations of RottL 
+ RottM + RottH versus non-Rottweiler dogs were 11.36 
pg/mL and 14.09 pg/mL respectively. There were no 
significant differences between RottH + RottM versus 
RottL + N, or between breeds (Figure 4).  Figure 2. Plots of the relative copy number from QRT-PCR 
assays for IFN-. The horizontal line corresponds to the 
median value of that group. There were no significant dif-
ferences in the transcription of mRNA encoding IFN- be-
tween the groups, although there was a tendency for IFN- 
mRNA expression to be lower in the diseased group versus 
the control dogs. 
3.5. Correlation of Quantification of IL-5 and 
IFN- mRNA and Protein Quantified by 
ELISA 
In this study, plasma IL-5 and IFN- measured by ELISA 
 
Table 1. Results of quantification of transcripts for IL-4, IL-5, IL-10, IL-12p19, IL-12p35, IL-12p40, IL-18, and IFN-γ: All 
results were expressed relative to the sample with the fewest number of gene copies for each target (not always the same sam-




IL-4 IL-5 IL-10 IL-12p19 IL-12p35 IL-12p40 IL-18 IFN- 
N 0 1.0 3.8 2.6 1.8 2.1 1.8 1.0 15.7 
N 0.2 9.4 1.0 3.0 2.1 1.0 3.4 1.9 22.0 
N 0.3 9.4 2.4 4.3 2.0 3.2 5.5 3.8 7.5 
N 0.1 24.7 1.6 1.0 1.0 1.4 1.0 3.9 90.5 
N 0.1 6.2 3.3 3.4 3.2 1.5 5.3 3.4 26.9 
RottL 0.3 20.9 4.3 1.2 3.3 1.2 5.1 1.4 6.6 
RottL 0.5 8.4 2.8 2.3 2.2 3.7 4.7 5.3 301.8 
RottL 0.6 4.9 1.6 2.3 1.5 2.0 3.8 2.4 16.1 
RottL 1 12.0 4.6 1.9 2.2 1.5 2.1 5.4 16.1 
RottL 0.6 5.9 3.0 2.3 2.6 1.5 2.4 3.1 3.4 
RottL 0.7 10.2 2.1 2.0 1.5 1.0 7.3 4.0 20.7 
RottM 0.9 17.1 1.6 3.7 2.0 1.8 3.3 2.9 10.4 
RottM 0.7 11.4 2.3 3.2 3.6 2.1 5.8 3.4 5.1 
RottM 0.8 6.0 2.8 1.3 2.9 1.3 5.3 5.4 1.0 
RottM 0.9 11.3 4.6 1.7 3.2 1.4 5.4 3.7 16.3 
RottM 1.1 5.7 2.0 1.7 2.0 1.3 5.6 2.5 7.6 
RottM 1.2 9.0 4.1 2.3 2.1 5.2 2.0 2.7 31.7 
RottM 0.7 29.3 1.4 3.4 2.0 2.1 2.9 3.0 9.5 
RottH 2 72.9 3.4 4.6 2.6 2.8 2.2 2.5 7.0 
RottH 2.3 2.0 1.6 2.9 2.3 1.3 5.9 3.5 9.0 
RottH 3.6 174.9 4.6 3.2 1.5 2.3 3.3 6.5 11.9 




                         N+RottL           RottM + RottH 
Figure 3. Plot of the concentrations of serum IFN- deter-
mined by ELISA. The horizontal line corresponds to the 
median value of that group. There were no significant dif-
ferences between normal and diseased animals in the con-
centration of plasma IFN-γ quantified by ELISA. 
 
IL-5 




RottL+RottM+RottH             N      
Figure 4. Plots of serum IL-5 concentrations quantified by 
ELISA. The horizontal line corresponds to the median 
value of that group. There were no significant differences 
between normal and diseased animals in the concentration 
of plasma IL-5 quantified by ELISA, or between Rottweil-
ers and non-Rottweiler dogs. 
was poorly correlated with mRNA encoding IL-5 and 
IFN-γ quantified through RT-PCR. The correlation coef-
ficients for IL-5 and IFN- were 0.1101 and −0.108, re-
spectively. 
4. Discussion 
To our knowledge, this is the first study reporting quanti-
fication of mRNA encoding cytokines in dogs with pe-
ripheral blood eosinophilia.  
IFN-γ is a pro-inflammatory cytokine that is predomi-
nantly produced by type 1 (Th1) cells and natural killer 
cells upon activation by IL-12 [1]. Decreased IFN-, and 
by association down-regulation of the Th1 response, may 
be observed with eosinophilia in people? [26]. This ob-
servation suggests that IFN- is unlikely to play a major 
role in HES, and therefore should be expressed at lower 
levels in dogs with eosinophilia than in those without. 
However, as there was no difference in IFN-γ, as deter-
mined by mRNA or ELISA, the role of IFN- in canine 
eosinophil physiology remains unknown.  
Increased IL-5 plasma concentrations have been dem-
onstrated in a proportion of people diagnosed with HES 
[27]. However, this production is unrelated to aetiology 
(neoplastic vs. idiopathic) and is thought to be a conse-
quence of the eosinophils themselves rather than the 
cause of the eosinophilia [1,2,13,27].  
The lack of significant differences in mRNA and pro-
tein concentrations of IL-5 between groups in our study 
could be due to factors such as time of sampling and the 
type of samples collected. Circulating IL-5 concentra-
tions have been observed to rise approximately two to 
four weeks preceding peripheral eosinophilia in some 
people [27], whilst episodic increases in IL-5 concentra-
tions have been noted in others [27]. Therefore, serial 
sampling may have proved more useful in determining 
IL-5 trends in this study. It is also possible that blood 
concentration of IL-5 does not reflect tissue concentra-
tions, and measurement of IL-5 in bone marrow or intes-
tinal tissue may have produced different results. Such a 
level of invasive diagnostic sampling was not possible in 
this population of dogs. The small number of affected 
dogs assessed, the lack of serial sampling, and the vari-
able clinical presentations were also factors that could 
have contributed to a lack of obvious differences in cyto-
kine profiles. 
It is also possible that eosinophilia in Rottweilers does 
not occur in response to IL-5-mediated mechanisms. 
Monoclonal expansion of the eosinophils themselves, 
independent of cytokine stimulation, has been described 
in people [5]. Investigation into other cytokines that 
stimulate eosinophil production, such as IL-3 or granu-
locyte-monocyte colony stimulating factor (GM-CSF) 
may shed more light on the immunopathogenesis of 
eosinophilia in dogs.  
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There has been a focus on the development of anti- 
IL-5 therapy in the management of eosinophilic disorders 
in man [27]. Studies assessing two different anti-IL-5 
antibodies; SCH55700 (Schering-Plough, Deerfield, ILL) 
and mepolizumab (GlaxoSmithKline, London, UK) de- 
monstrated effective and prolonged control of peripheral 
eosinophilia in people, regardless of underlying cause, 
disease variant, or baseline IL-5 concentration [14,27]. 
Although significantly increased IL-5 concentrations in 
our eosinophilic dogs would have lent weight to use of 
anti-IL-5 antibodies, normal baseline IL-5 concentrations 
should not preclude further investigation into its use. 
Additional studies are needed to determine safety, effi-
cacy, optimal dosing, as well as observation for rebound 
eosinophilia in the canine model.  
Eotaxins serve as chemoattractants mainly for eosino-
phils via inducing processes such as actin polymerization 
[15,16,28]. Eotaxins are produced by various tissue 
sources such as bronchial epithelial and intestinal cells 
and increased plasma eotaxin concentrations have been 
documented in people with allergic disease amongst oth-
ers [29-32]. There is minimal information regarding 
plasma detection of eotaxins in dogs, with most veteri-
nary studies reporting the detection and quantification of 
eotaxin-2 and -3 in tissue samples [17,21,33]. Inability to 
detect expression of eotaxin mRNA in our cohort of dogs 
with eosinophilia was unexpected. Furthermore, daily 
fluctuations in canine plasma eotaxin concentrations 
have not been investigated. As previously, the small 
number of dogs assessed, and the type of sample as-
sessed may also have influenced the results. 
5. Conclusion 
In summary, there was no significant difference in cyto-
kine mRNA expression (IL-4, -5, -10, -12p19, -12p35, 
-12p40, -18, and IFN-γ) and quantification via ELISA of 
IL-5 and IFN-γ in blood between Rottweilers with vary-
ing degrees of eosinophilia compared to Rottweiler with 
normal eosinophil counts and health dogs of other breeds. 
Additional genetic, molecular, cytokine and chemokine 
studies including larger numbers of affected dogs are 
warranted before accurate conclusions can be made about 
the pathogenesis of eosinophilic disease in Rottweilers. 
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Supplementary Table A1. Primer and probe sequences used for quantitative RT-PCR. 
Forward Primer Reverse Primer Probe Primer 
Set 
Product 















RPL13A 87 GCCGGAAGGTTGTAGTCGT GGAGGAAGGCCAGGTAATTC 
FAM-TGTGAAGGCATCAACATTTCTGGC
A-BHQ-1 
RPS18 116 TGCTCATGTGGTATTGAGGAA TCTTATACTGGCGTGGATTCTG
FAM-CACTGAGGATGAGGTGGAACGTGT
G-BHQ-1 









YWHAZ 94 CGAAGTTGCTGCTGGTGA TTGCATTTCCTTTTTGCTGA 
FAM-AGGGATTGTGGATCAGTCACAACA
AGC-BHQ-1 
IL-4 123 GCTCCAAAGAACACAAGCGA CATGCTGCTGAGGTTCCTGT 
Texas Red-TGCAGAGCTGCTACTGTACTG 
CGGC-ELLE 
IL-5 158 GACTGGTGGCAGAGACCTTGA CGTGGGCAGTTTGGTTCTTC 
FAM-CGAACTTGGCTGATAGGCGATGG-B
HQ-1 
IL-10 101 CGACCCAGACATCAAGAACC CACAGGGAAGAAATCGGTGA 
FAM-TCCCTGGGAGAGAAGCTCAAGACC
C-BHQ-1 
IL-12p19 108 GTGATCCCCAAGGACTCAAA GCTCCCCTGTGAAAATGTCT 
FAM-AAAGGATCCACCAGGGCCTGG-BH
Q-1 























Eotaxin-3 128 TCTGCTGCTTCCAATATAGCC TGCACAGACTTTATGGCCTTT 
FAM-AGCTGCTCCCAGCAGGCTGTGATA
T-BHQ-1 
 
